TY - JOUR
T1 - Synthesis and evaluation of novel lidocaine sulfur analogs
AU - Loftsson, Thorsteinn
AU - Matsuo, Masaaki
AU - Caldwell, Robert W.
AU - Gildersleeve, Nancy
AU - Bodor, Nicholas
PY - 1984/12
Y1 - 1984/12
N2 - In order to test whether the structural requirement for basic or quaternary nitrogen in antiarrhythmic drugs is essential, several sulfur-containing lidocaine analogs were synthesized and their metabolism investigated in human plasma, various esterase preparations, bovine liver microsomes, and in vivo in rats. Skin diffusion was measured through hairless mouse skin. Two of the compounds were found to have long-lasting antiarrhythmic activity in dogs, and in the case of the ethylthio analog, activity equivalent to that of lidocaine persisted without the presence of an ionized group to interact with the proposed anionic portion of membrane polypeptides. Thus, non-specific antiarrhythmic activity is possible when only the myocardial membrane phospholipids interact with the drug and charge attractions between the drug and membrane peptide groups are not necessary.
AB - In order to test whether the structural requirement for basic or quaternary nitrogen in antiarrhythmic drugs is essential, several sulfur-containing lidocaine analogs were synthesized and their metabolism investigated in human plasma, various esterase preparations, bovine liver microsomes, and in vivo in rats. Skin diffusion was measured through hairless mouse skin. Two of the compounds were found to have long-lasting antiarrhythmic activity in dogs, and in the case of the ethylthio analog, activity equivalent to that of lidocaine persisted without the presence of an ionized group to interact with the proposed anionic portion of membrane polypeptides. Thus, non-specific antiarrhythmic activity is possible when only the myocardial membrane phospholipids interact with the drug and charge attractions between the drug and membrane peptide groups are not necessary.
UR - http://www.scopus.com/inward/record.url?scp=0021682333&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021682333&partnerID=8YFLogxK
U2 - 10.1016/0378-5173(84)90035-8
DO - 10.1016/0378-5173(84)90035-8
M3 - Article
AN - SCOPUS:0021682333
SN - 0378-5173
VL - 22
SP - 345
EP - 355
JO - International Journal of Pharmaceutics
JF - International Journal of Pharmaceutics
IS - 2-3
ER -